Novel therapies in clinical use for the management of hyperlipidaemia

Mettananda, C.

dc.contributor.author	Mettananda, C.
dc.date.accessioned	2023-11-09T04:49:05Z
dc.date.available	2023-11-09T04:49:05Z
dc.date.issued	2023
dc.identifier.citation	Asian Journal of Internal Medicine.2023;2(2):35-38	en_US
dc.identifier.issn	2827-7260 (Print)
dc.identifier.uri	http://repository.kln.ac.lk/handle/123456789/27035
dc.description	Not Indexed	en_US
dc.description.abstract	Optimal control of low-density lipoprotein cholesterol (LDLc) is identified as a major target in reducing cardiovascular disease burden globally. However, existing lipid-lowering therapies have not been able to achieve LDLc targets even in developed countries. Therefore, novel therapies for the management of hyperlipidaemia are being trialled. Currently, there are three main groups of newer medicines; bempedoic acid, PCSK9 inhibitors and inclisiran, in addition to statins and ezetimibe in use for the management of hyperlipidaemia. This article aims to introduce these newer medicines and their clinical use in the treatment of hyperlipidaemia.	en_US
dc.language.iso	en	en_US
dc.publisher	Sri Lanka College of Internal Medicine	en_US
dc.subject	Novel therapies	en_US
dc.subject	Hyperlipidaemia	en_US
dc.subject	LDL	en_US
dc.subject	Bempedoic acid	en_US
dc.subject	PCSK9 inhibitors	en_US
dc.subject	Inclisiran	en_US
dc.subject	siMRNA	en_US
dc.title	Novel therapies in clinical use for the management of hyperlipidaemia	en_US
dc.type	Article	en_US